| 臺大學術典藏 |
2020-08-12T06:34:12Z |
Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women
|
Lin H.-C.; Chen H.-L.; Fang Y.-H.; Tsai F.-Y.; Hsieh W.-S.; Yu J.; Stevens V.L.; Laird-Offringa I.A.; Marconett C.N.; Rieswijk L.; Chao A.; Yang P.-C.; Shu X.-O.; Wu T.; Wu Y.L.; Lin D.; Chen K.; Zhou B.; Wu G.; Tsugane S.; Zhu J.; Yang K.; Jiang G.; Fei K.; Shimazu T.; Liu J.; Yamaji T.; Hicks B.; Wyatt K.; Li S.A.; Dai J.; Ma H.; Jin G.; Song B.; Wang Z.; Cheng S.; Li X.; Ren Y.; Cui P.; Iwasaki M.; Lan Q.; Rothman N.; Huang Y.-C.; Kohno T.; Shen H.; Chanock S.J.; Chung C.C.; Burdett L.; Yeager M.; Hutchinson A.; Berndt S.I.; Wu W.; Pang H.; Li Y.; Choi J.E.; Park K.H.; Sung S.W.; Liu L.; Kang C.H.; Zhu M.; Chen C.-H.; Yang T.-Y.; Xu J.; Guan P.; Tan W.; Wang C.-L.; Hsin M.; Sit K.-Y.; Chen T.-Y.; Jin L.; Wu J.; Lim W.-Y.; Chen K.-C.; Li Y.-J.; Li J.; Chen H.; CHONG-JEN YU; Vermeulen R.; Choi Y.Y.; Hung J.-Y.; Kim J.S.; Yoon H.I.; Lin C.-C.; Park I.K.; Xu P.; Wang Y.; He Q.; Perng R.-P.; Chen C.-Y.; Jiang S.-S.; Chen Y.; Ho J.; Wang W.-C.; Hu Z.; Guo H.; Jung Y.J.; Tsai Y.-H.; Sung J.S.; Hsiao C.-F.; Jeon H.-S.; Lu D.; Liu J.; Wong J.Y.Y.;Zhang H.;Hsiung C.A.;Shiraishi K.;Yu K.;Matsuo K.;Wong M.P.;Hong Y.-C.;Wang J.;Seow W.J.;Wang Z.;Song M.;Kim H.N.;Chang I.-S.;Chatterjee N.;Hu W.;Wu C.;Mitsudomi T.;Zheng W.;Kim J.H.;Seow A.;Caporaso N.E.;Shin M.-H.;Chung L.P.;An S.-J.;Wang P.;Yang Y.;Zheng H.;Yatabe Y.;Zhang X.-C.;Kim Y.T.;Cai Q.;Yin Z.;Kim Y.-C.;Bassig B.A.;Chang J.;Ho J.C.M.;Ji B.-T.;Daigo Y.;Ito H.;Momozawa Y.;Ashikawa K.;Kamatani Y.;Honda T.;Hosgood H.D.;Sakamoto H.;Kunitoh H.;Tsuta K.;Watanabe S.-I.;Kubo M.;Miyagi Y.;Nakayama H.;Matsumoto S.;Tsuboi M.;Goto K.;Shi J.;Song L.;Hua X.;Takahashi A.;Goto A.;Minamiya Y.;Shimizu K.;Tanaka K.;Wei F.;Matsuda F.;Su J.;Kim Y.H.;Oh I.-J.;Song F.;Su W.-C.;Chen Y.-M.;Chang G.-C.;Chen K.-Y.;Huang M.-S.;Chien L.-H.;Xiang Y.-B.;Park J.Y.;Kweon S.-S.;Chen C.-J.;Lee K.-M.;Blechter B.;Li H.;Gao Y.-T.;Qian B.;Lu D.;Liu J.;Jeon H.-S.;Hsiao C.-F.;Sung J.S.;Tsai Y.-H.;Jung Y.J.;Guo H.;Hu Z.;Wang W.-C.;Chung C.C.;Burdett L.;Yeager M.;Hutchinson A.;Berndt S.I.;Wu W.;Pang H.;Li Y.;Choi J.E.;Park K.H.;Sung S.W.;Liu L.;Kang C.H.;Zhu M.;Chen C.-H.;Yang T.-Y.;Xu J.;Guan P.;Tan W.;Wang C.-L.;Hsin M.;Sit K.-Y.;Ho J.;Chen Y.;Choi Y.Y.;Hung J.-Y.;Kim J.S.;Yoon H.I.;Lin C.-C.;Park I.K.;Xu P.;Wang Y.;He Q.;Perng R.-P.;Chen C.-Y.;Vermeulen R.;Wu J.;Lim W.-Y.;Chen K.-C.;Li Y.-J.;Li J.;Chen H.;Chong-Jen Yu;Jin L.;Chen T.-Y.;Jiang S.-S.;Liu J.;Yamaji T.;Hicks B.;Wyatt K.;Li S.A.;Dai J.;Ma H.;Jin G.;Song B.;Wang Z.;Cheng S.;Li X.;Ren Y.;Cui P.;Iwasaki M.;Shimazu T.;Tsugane S.;Zhu J.;Yang K.;Jiang G.;Fei K.;Wu G.;Lin H.-C.;Chen H.-L.;Fang Y.-H.;Tsai F.-Y.;Hsieh W.-S.;Yu J.;Stevens V.L.;Laird-Offringa I.A.;Marconett C.N.;Rieswijk L.;Chao A.;Yang P.-C.;Shu X.-O.;Wu T.;Wu Y.L.;Lin D.;Chen K.;Zhou B.;Huang Y.-C.;Kohno T.;Shen H.;Chanock S.J.;Rothman N.;Lan Q.; Mitsudomi T.; Zheng W.; Wu C.; Hu W.; Chatterjee N.; Chang I.-S.; Kim H.N.; Song M.; Wang Z.; Seow W.J.; Wang J.; Zhang H.; Hsiung C.A.; Shiraishi K.; Yu K.; Matsuo K.; Wong M.P.; Hong Y.-C.; Wong J.Y.Y.; Tsuta K.; Kunitoh H.; Sakamoto H.; Hosgood H.D.; Honda T.; Kamatani Y.; Ashikawa K.; Momozawa Y.; Ito H.; Daigo Y.; Yin Z.; Kim Y.-C.; Bassig B.A.; Chang J.; Ho J.C.M.; Ji B.-T.; Cai Q.; Kim J.H.; Seow A.; Caporaso N.E.; Shin M.-H.; Chung L.P.; An S.-J.; Wang P.; Yang Y.; Zheng H.; Yatabe Y.; Zhang X.-C.; Kim Y.T.; Chen Y.-M.; Su W.-C.; Tanaka K.; Wei F.; Matsuda F.; Su J.; Kim Y.H.; Oh I.-J.; Song F.; Shimizu K.; Watanabe S.-I.; Kubo M.; Miyagi Y.; Nakayama H.; Matsumoto S.; Tsuboi M.; Goto K.; Shi J.; Song L.; Hua X.; Takahashi A.; Goto A.; Minamiya Y.; Qian B.; Gao Y.-T.; Xiang Y.-B.; Park J.Y.; Kweon S.-S.; Chen C.-J.; Lee K.-M.; Blechter B.; Li H.; Chien L.-H.; Chang G.-C.; Chen K.-Y.; Huang M.-S. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Chao-Chi Ho;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Yu C.-J.; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:14Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-10T08:16:41Z |
Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis
|
Wang, J.-D.; KAI-PING GRACE YAO; Yao, G.; Wu, T.-Y.; Su, W.-C.; Lai, W.-W.; Wang, W.-C.; Lin, C.-Y.;Hwang, J.-S.;Wang, W.-C.;Lai, W.-W.;Su, W.-C.;Wu, T.-Y.;Yao, G.;Wang, J.-D.; Lin, C.-Y.; Hwang, J.-S. |
| 臺大學術典藏 |
2020-07-03T08:28:28Z |
The strategies to DVI challenges in Typhoon Morakot
|
Tsai H.-S.; Pan C.-H.; Chiang H.-M.; Liu H.-L.; Su W.-C.; Wu K.-T.; Chao C.-H.; Huang N.-E.; Yang K.-D.; Hsieh H.-M.; Tsai L.-C.; Linacre A.; Yu Y.-J.; Lin Y.-Y.; Chu P.-C.; JAMES CHUN-I LEE; Chen L.-J.; Yuan C.-H.; Lin C.-Y.; Huang T.-Y.; Shih H.-C.; Lin C.-Y. ;Huang T.-Y. ;Shih H.-C. ;Yuan C.-H. ;Chen L.-J. ;Tsai H.-S. ;Pan C.-H. ;Chiang H.-M. ;Liu H.-L. ;Su W.-C. ;Wu K.-T. ;Chao C.-H. ;Huang N.-E. ;Yang K.-D. ;Hsieh H.-M. ;Tsai L.-C. ;Linacre A. ;Yu Y.-J. ;Lin Y.-Y. ;Chu P.-C. ;James Chun-I Lee |
| 臺大學術典藏 |
2020-07-01T08:53:22Z |
Postural Control and Interceptive Skills in Children with Autism Spectrum Disorder
|
Chen L.-C.;Su W.-C.;Ho T.-L.;Lu L.;Tsai W.-C.;Chiu Y.-N.;Suh-Fang Jeng; Chen L.-C.; Su W.-C.; Ho T.-L.; Lu L.; Tsai W.-C.; Chiu Y.-N.; SUH-FANG JENG |
| 臺大學術典藏 |
2020-06-30T08:10:04Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
KANG-YI SU; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; Yu C.-J.; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; Chen H.-W.; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C.; Chen H.-Y.;Yu S.-L.;Ho B.-C.;Kang-Yi Su;Hsu Y.-C.;Chang C.-S.;Li Y.-C.;Yang S.-Y.;Hsu P.-Y.;Ho H.;Chang Y.-H.;Chen C.-Y.;Yang H.-I.;Hsu C.-P.;Yang T.-Y.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Hsia J.-Y.;Chuang C.-Y.;Yuan S.;Lee M.-H.;Liu C.-H.;Wu G.-I.;Hsiung C.A.;Chen Y.-M.;Wang C.-L.;Huang M.-S.;Yu C.-J.;Chen K.-Y.;Tsai Y.-H.;Su W.-C.;Chen H.-W.;Chen J.J.W.;Chen C.-J.;Chang G.-C.;Yang P.-C.;Li K.-C.; Ho B.-C.; Yu S.-L.; Chen H.-Y. |
| 臺大學術典藏 |
2020-06-18T06:09:56Z |
Chloroboron subphthalocyanine/C60 planar heterojunction organic solar cell with N,N-dicarbazolyl-3,5-benzene blocking layer
|
Chen, L.-C.;Lee, J.-H.;Chen, C.-T.;Han, H.-C.;Chiu, T.-L.;Su, W.-C.;Lee, C.-C.;Liu, S.-W.;Wei, M.-K.;Bardeen, C.J.;Cheng, Y.-C.;Nichols, V.M.;Lin, C.-F.; Lin, C.-F.; Nichols, V.M.; Cheng, Y.-C.; Bardeen, C.J.; Wei, M.-K.; Liu, S.-W.; Lee, C.-C.; Su, W.-C.; Chiu, T.-L.; Han, H.-C.; Chen, L.-C.; Chen, C.-T.; Lee, J.-H. |
| 臺大學術典藏 |
2020-06-18T06:09:53Z |
A new anodic buffer layer material for non-mixed planar heterojunction chloroboron subphthalocyanine organic photovoltaic achieving 96% internal quantum efficiency
|
Chen, L.-C.;Lee, J.-H.;Chen, C.-T.;Han, H.-C.;Chiu, T.-L.;Huang, J.-C.;Su, W.-C.;Kubota, M.;Sakurai, T.;Lee, C.-C.;Liu, S.-W.;Lin, C.-F.; Lin, C.-F.; Liu, S.-W.; Lee, C.-C.; Sakurai, T.; Kubota, M.; Su, W.-C.; Huang, J.-C.; Chiu, T.-L.; Han, H.-C.; Chen, L.-C.; Chen, C.-T.; Lee, J.-H. |
| 臺大學術典藏 |
2020-06-17T03:01:38Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
Chen H.-Y.;Sung-Liang Yu;Ho B.-C.;Su K.-Y.;Hsu Y.-C.;Chang C.-S.;Li Y.-C.;Yang S.-Y.;Hsu P.-Y.;Ho H.;Chang Y.-H.;Chen C.-Y.;Yang H.-I.;Hsu C.-P.;Yang T.-Y.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Hsia J.-Y.;Chuang C.-Y.;Yuan S.;Lee M.-H.;Liu C.-H.;Wu G.-I.;Hsiung C.A.;Chen Y.-M.;Wang C.-L.;Huang M.-S.;Yu C.-J.;Chen K.-Y.;Tsai Y.-H.;Su W.-C.;Chen H.-W.;Chen J.J.W.;Chen C.-J.;Chang G.-C.;Yang P.-C.;Li K.-C.; Chen H.-Y.; SUNG-LIANG YU; Ho B.-C.; Su K.-Y.; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; Yu C.-J.; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; Chen H.-W.; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C. |
| 臺大學術典藏 |
2020-06-11T06:17:54Z |
High-performance organic photovoltaic device using a new amorphous molecular material of bis(4-(N-(l-naphthyl)phenylamino) phenyl)fumaronitrile
|
Liu, S.-W.;Lee, C.-C.;Su, W.-C.;Lin, C.-F.;Huang, J.-C.;Chen, C.-T.;Lee, J.-H.; Liu, S.-W.; Lee, C.-C.; Su, W.-C.; Lin, C.-F.; Huang, J.-C.; Chen, C.-T.; Lee, J.-H.; JIUN-HAW LEE |
| 臺大學術典藏 |
2020-05-26T09:27:22Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Kao W.-Y.;Lin Z.-Z;Yu C.-T;Kuo H.-P;Chang W.-C;Yu C.-J;Chung C.-Y;Ho M.-L;Wang J.-L;Huang M.-S;Chen C.-H;Chen H.-C;Hsia T.-C;Tsao C.-J;Su W.-C;Lai R.-S;Chu N.-M;Hsieh R.-K;Lin M.-C;Chang G.-C;Chen Y.-M;Chih-Hsin Yang;Perng R.-P; Perng R.-P; CHIH-HSIN YANG; Chen Y.-M; Chang G.-C; Lin M.-C; Hsieh R.-K; Chu N.-M; Lai R.-S; Su W.-C; Tsao C.-J; Hsia T.-C; Chen H.-C; Chen C.-H; Huang M.-S; Wang J.-L; Ho M.-L; Chung C.-Y; Yu C.-J; Chang W.-C; Kuo H.-P; Yu C.-T; Lin Z.-Z; Kao W.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma
|
Park K.;Close S;Garrus J.E;Payumo F;Komarnitsky P;Han M;Chang G.-C;Chih-Hsin Yang;Tan E.-H;Su W.-C;Geater S.L;Mok T.S.K; Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
|
Lux-Lung 5 Investigators;Serwatowski P;Kazarnowicz A;Jaskiewicz P;Palomino O.L.M;Pantigoso W.R;Barreda R.L.A;S?nchez J.F.S;Gans S;Herder G;Dingemans A.-M;Stigt J;Aerts J;Baca O.P;Luna G.A;Perez J.L.G;Delgado F.G;Cruciani G;Ceresoli G.L;Platania M;Milandri C;Gridelli C;Bearz A;Bidoli P;Migliorino M.R;Stemmer S;Gottfried M;Onn A;Nagarkar R.V;Dadhich H;Sharma L;Venkatesan S;Jain M;Prabhash K;Sarosi V;Strausz J;Tehenes S;Mark Z;Wiewrodt R;Dickgreber N;Huber R;Von Pawel J;Laack E;Keilholz U;Faehling M;Wehler T;Thomas M;Coudert B;Rotarski M;Gervais R;Fournel P;Bennouna J;Planchard D;Perol M;Sibilot D.M;Zalcman G;Chouaid C;Cadranel J;Alanko T;Riska H;Zadra C.A;Garicochea B;Zereu M;Lu S;Zhang Y;Huang J;Feng J;Qin S;Cheng Y;Liu X;Wu Y;Lin X;Thropay J;Meza L;Gurtler J;Summers Y;Upadhyay S;Brown E;Talbot T;Toy E;Spicer J;Popat S;Mitra S;Shah R;Polishchuk I;Bondarenko I;Ponomarova O;Popovych O;Vinnyk Y;Hsieh R.-K;Ho C.-L;Huang M.-S;Su W.-C;Tsao T.C.-Y;Chang G.-C;Tsai Y.-H;Chen Y.-M;Hsia T.-C;Yang C.-H;Kim Y.-C;Han J.-Y;Kim J.-H;Park K;Kim S.-W;Kim D.-W;Felip E;Cobo M;Lianes P;Campelo R.G;Camps C;Larriba J.L.G;Garrido P;Ragulin Y;Orlov S;Karaseva N;Lubennikov V;Jassem J;Szczesna A;Huang C;Wang J;Zhou C;Vercauter P;Delval L;Lambrechts M;Galdermans D;Carestia L;Bustin F;Humblet Y;Greil R;Mainwaring P;Crombie C;Underhill C;Parente P;Mclachlan S.-A;Richardet M;Blajman C;Zarba J.J;Recondo G;Martin C.M;Bagnes C;Planchard D;Chand V.K;Wang B;Zhou C;Wiewrodt R;Vinnyk Y;Strausz J;Lu S;Liu X;Kim D.-W;Grossi F;Feng J.-F;De Marinis F;Chouaid C;Chen Y.-M;Bennouna J;Kim J.-H;Park K;Chih-Hsin Yang;Schuler M; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators; Schuler M; CHIH-HSIN YANG; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors
|
Hsiung C.A.;Yang P.-C;Chanock S.J;Chen C.-J;Rothman N;Lan Q;Yang T.-Y;Shieh S.-H;Shih W.-C;Hsieh W.-S;Su Y.-C;Tsai Y.-H;Huang M.-S;Chen Y.-M;Wang W.-C;Chen K.-Y;Lo F.-Y;Wang Z;Chang G.-C;Chen C.-H;Chen C.-Y;Lee J.-H;Hsiao C.-F;Chien L.-H;Su W.-C;Chih-Hsin Yang;Jiang S.S;Chang I.-S; Chang I.-S; Jiang S.S; CHIH-HSIN YANG; Su W.-C; Chien L.-H; Hsiao C.-F; Lee J.-H; Chen C.-Y; Chen C.-H; Chang G.-C; Wang Z; Lo F.-Y; Chen K.-Y; Wang W.-C; Chen Y.-M; Huang M.-S; Tsai Y.-H; Su Y.-C; Hsieh W.-S; Shih W.-C; Shieh S.-H; Yang T.-Y; Lan Q; Rothman N; Chen C.-J; Chanock S.J; Yang P.-C; Hsiung C.A. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
|
Stadler W.M; Vaughn D.J; Sonpavde G; Vogelzang N.J; Tagawa S.T; Petrylak D.P; Rosen P; Chia-Chi Lin; Mahoney J; Modi S; Lee P; Ernstoff M.S; Su W.-C; Spira A; Pilz K; Vinisko R; Schloss C; Fritsch H; Zhao C; Carducci M.A. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:19Z |
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1)
|
De Santis M; Wiechno P.J; Bellmunt J; Lucas C; Su W.-C; Albiges L; Chia-Chi Lin; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl W.C; Retz M.M; Vaissi?re N; Culine S. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
|
Weiss G.J.;Zhang Z.-Y;Chan J;Hughes L;Bobilev D;Su W.-C;Dziadziuszko R;Mita M;de Castro Carpe?o J;Sachdev J;Lu S;Arkenau H.-T;Chia-Chi Lin; Chia-Chi Lin; Arkenau H.-T; Lu S; Sachdev J; de Castro Carpe?o J; Mita M; Dziadziuszko R; Su W.-C; Bobilev D; Hughes L; Chan J; Zhang Z.-Y; Weiss G.J. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-03-24T07:00:40Z |
Factors associated with myocardial infarction after emergency endoscopy for upper gastrointestinal bleeding in high-risk patients: a prospective observational study
|
Wang H.-P.;Lin J.-T.;CHIEN-HUA HUANG;Su W.-C.;Tai C.-M.;Chiang T.-H.;Cheng T.-Y.;Huang S.-P.;Lee C.-T.; Lee C.-T.; Huang S.-P.; Cheng T.-Y.; Chiang T.-H.; Tai C.-M.; Su W.-C.; CHIEN-HUA HUANG; Lin J.-T.; Wang H.-P. |
| 臺大學術典藏 |
2020-03-05T08:16:37Z |
Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice
|
Chen Y.-C.;Su Y.-C.;Shieh G.-S.;Su B.-H.;Su W.-C.;Pei-Hsin Huang;Jiang S.-T.;Shiau A.-L.;Wu C.-L.; Chen Y.-C.; Su Y.-C.; Shieh G.-S.; Su B.-H.; Su W.-C.; PEI-HSIN HUANG; Jiang S.-T.; Shiau A.-L.; Wu C.-L. |
| 臺大學術典藏 |
2020-03-02T07:41:00Z |
Polythiophene derivative comprising carbazoles as pendant groups for polymer solar cell applications
|
Wang, H.-J.; Chan, L.-H.; Chen, C.-P.; Lee, R.-H.; Su, W.-C.; Jeng, R.-J.; RU-JONG JENG |
| 臺大學術典藏 |
2020-03-02T07:40:59Z |
Iterative synthesis of monodisperse pendants for making comb-like polyurethanes
|
RU-JONG JENG; Chen, S.-C.; Tung, S.-H.; Lee, R.-H.; Su, W.-C.; Jeng, R.-J.; Wu, C.-H.; Chen, Y.-C.; Dai, S.A. |
| 臺大學術典藏 |
2020-03-02T07:40:52Z |
A Facile Synthetic Route to Ether Diols Derived from 1,1-Cyclopentylenylbisphenol for Robust Cardo-Type Polyurethanes
|
Wu, C.-H.; Lin, Y.-R.; Yeh, S.-C.; Huang, Y.-C.; Sun, K.-H.; Shih, Y.-F.; Su, W.-C.; Dai, C.-A.; Dai, S.A.; Jeng, R.-J.; RU-JONG JENG |
| 臺大學術典藏 |
2020-02-17T07:43:32Z |
Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression
|
Chang T.-S; Wu Y.-C; Chi C.-C; Su W.-C; Chang P.-J; Lee K.-F; Tung T.-H; Wang J; Liu J.-J; Tung S.-Y; Kuo L.-M; HONG-NERNG HO; Ling T.-Y; Huang Y.-H. |
| 臺大學術典藏 |
2020-02-15T03:52:38Z |
Employee ownership motivation and individual risk-taking behaviour: A cross-level analysis of Taiwan's privatized enterprises
|
Wu, H.-L.;Su, W.-C.;Lee, C.-Y.; Wu, H.-L.; Su, W.-C.; Lee, C.-Y.; HSUEH-LIANG WU |
| 臺大學術典藏 |
2020-02-14T07:49:07Z |
Employee ownership motivation and individual risk-taking behaviour: A cross-level analysis of Taiwan's privatized enterprises
|
Wu, H.-L.; Su, W.-C.; Lee, C.-Y.; HSUEH-LIANG WU |
| 臺大學術典藏 |
2020-02-14T02:49:50Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-02-11T07:58:53Z |
Tension pneumothorax after an ERCP in a patient with hepatic hydrothorax and sealed-off perforated duodenal ulcer
|
Han M.-L.; YAO-MING WU; Liu K.-L.; Su W.-C.; Wang H.-P. |
| 臺大學術典藏 |
2020-02-10T09:00:52Z |
Oral administration of a mite allergen expressed by zucchini yellow mosaic virus in cucurbit species downregulates allergen-induced airway inflammation and IgE synthesis
|
Hsu C.-H.;Lin S.-S.;Liu F.-L.;Su W.-C.;Yeh S.-D.; Hsu C.-H.; Lin S.-S.; Liu F.-L.; Su W.-C.; Yeh S.-D.; SHIH-SHUN LIN |
| 臺大學術典藏 |
2020-02-06T05:22:03Z |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
|
Iafrate A.J.;Chand V.K.;Lobmeyer M.T.;Le Maulf F.;Robohn M.;Su W.-C.;WEN-FANG CHENG;Lenz H.-J.;Becerra C.R.;Cohen S.M.;Shapiro G.I.;Kwak E.L.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J.; Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. |
| 臺大學術典藏 |
2020-01-06T03:03:53Z |
A Facile Synthetic Route to Ether Diols Derived from 1,1-Cyclopentylenylbisphenol for Robust Cardo-Type Polyurethanes
|
CHI-AN DAI; Jeng, R.-J.; Wu, C.-H.; Lin, Y.-R.; Yeh, S.-C.; Huang, Y.-C.; Sun, K.-H.; Shih, Y.-F.; Su, W.-C.; Dai, C.-A.; Dai, S.A. |
